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A retrospective analysis was performed to evaluate the clinical characteristics and prognostic factors in the patients with clear cell
carcinoma (CCC) of the ovary. After central pathological review and scanning of the medical records of nine Japanese institutions
between 1992 and 2003, a total of 254 patients with CCC of the ovary were enrolled in the present study. Mean age was 52.4 years
(range 23–73 years). Tumours were 13% (33/254) stage Ia, 36% (92/254) stage Ic, 13% (33/254) stage II, 30% (80/254) stage III, and
6% (16/254) stage IV. Five-year progression-free survival and overall survival was 84 and 88% in stage I, 57 and 70% in stage II, 25 and
33% in stage III and 0 and 0% in stage IV, respectively. Retroperitoneal lymph node metastasis was observed in 9% in pT1a tumours,
7% in pT1c tumours, 13% in pT2 tumours, and 58% in pT3 tumours, respectively. There was no survival benefit according to
chemotherapeutic differences in the patients who received complete surgical staging procedures and conventional chemotherapy.
Peritoneal cytological status was an independent prognostic factor in stage Ic patients (P¼0.03) and only residual tumour diameter
was an independent prognostic factor in stage III, IV patients (P¼0.02). Our results suggest that cytoreductive surgery resulting in no
residual tumour only could improve the prognosis of advanced CCC patients.
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Cancer of the ovary has the worst prognosis of all gynaecological
malignancies in the United States (Edwards et al, 2005) and Europe
(Bray et al, 2005). Survival rate of patients with ovarian cancer has
dramatically improved after introduction of platinum-based
chemotherapy, but there still exist a large number of patients
showing no response to the treatments. Although response to
anticancer drugs is not easy to predict, in vitro studies suggested
that acquired resistance to cisplatin has been associated with
increased levels of glutathione and glutathione-S-transferase
activity, increased metallothionein and decreased accumulation
of cisplatin (Kikuchi et al, 1998). Histological subtypes such as
clear cell carcinoma (CCC) and mucinous adenocarcinoma had
been suggested as one of the most reliable criteria predicting the
ineffectiveness of chemotherapy.
Clear cell carcinoma (CCC) was initially termed as meso-
nerhroid in 1939 (Schiller, 1939), and since 1973 it was strictly
defined by World Health Organization as lesions characterised by
clear cells growing in solid/tubular or glandular patterns as well as
hobnail cells (Serov et al, 1973). Since then, many literatures have
identified the distinctive behaviour of the tumors as compared
with other histological subtypes of ovarian neoplasms. The most
distinctive difference is that patients with CCC of the ovary have
lower response rate to anticancer drugs. To our knowledge, only a
few clinical studies have evaluated the response rates for CCC
patients with measurable disease. The response rate of chemo-
therapy for CCC was 11.1% with platinum-based regimens
(Sugiyama et al, 2000) and 22–56% with paclitaxel plus
carboplatin. (Enomoto et al, 2003; Ho et al, 2004).
Another factor that might contribute to prognosis of ovarian
cancer is the degree of cytoreductive surgery including lympha-
denectomy. Complete surgical staging including para-aortic
lymphadenectomy might influence the prognosis in early-stage
CCC cases (Ho et al, 2003). Furthermore, the patients with pure-
type CCC had worse overall survival than those with mixed-type
CCC (Ho et al, 2004).
To evaluate the clinical characteristics of the patients with CCC
of the ovary and to determine the impact of surgery and
Received 27 January 2006; revised 24 March 2006; accepted 27 March
2006; published online 25 April 2006
*Correspondence: Dr M Takano, Institute of Reproductive and
Developmental Biology (IRDB), Imperial College of London, Hammer-
smith Hospital, DuCane Road, London W12 0NN, London, UK;
E-mail: m.takano@imperial.ac.uk
British Journal of Cancer (2006) 94, 1369–1374
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
schemotherapy on prognosis of those patients, we conducted a
retrospective study over 11-year period of a sample of 254 patients
diagnosed with pure-type CCC in the departments of nine Japanese
institutions.
MATERIALS AND METHODS
Patients and tumours
Between 1992 and 2002, 254 patients with CCC of the ovary were
identified by scanning the medical records of the collaborating
institutions and central pathological review. Patients received
initial treatment and follow-up at nine institutions belonging to
Japan Clear Cell Carcinoma Study Group; National Defence
Medical College Hospital, Tohoku University Hospital, Aichi
Cancer Center Hospital, Osaka Medical College Hospital, Osaka
City General Hospital, Jichi Medical College Hospital, Tottori
University Hospital, Kobe National Hospital, Iwate Medical
College Hospital.
Initially, 337 patients were accrued from medical records of each
institution. All pathological specimens from primary surgery were
reviewed under central pathological review by two independent
pathologists with no knowledge of patients’ clinical data. Tumours
were diagnosed as CCC if typical clear or hobnail cells growing in a
papillary, solid, or tubulocystic pattern appeared in 490% of all
pathological specimens. After pathological review, three cases were
excluded; two diagnosed as mixed epithelial ovarian cancers and
the other diagnosed as CCC derived from mature cystic teratoma,
and 334 cases were identified as the patients with pure-type CCC of
ovary. In those patients, 80 patients were excluded owing to
insufficient surgery lacking complete surgical staging procedures:
13 cases in pT1a tumours, 51 cases in pT1c tumours, 16 cases in
pT2 tumours, respectively. The rest 254 patients were enrolled on
the present study. Patients of FIGO stage Ic were classified into
three subtypes according to pathological characteristics; Ic
(capsule ruptured) for the patients with ruptured capsule at
laparotomy, Ic (ovarian surface) for those with tumour on ovarian
surface, and Ic (ascites/malignant washing) for those with positive
malignant cells in the ascites or positive peritoneal washing.
All 254 patients underwent complete surgical staging procedures
including hysterectomy, bilateral salpingo-oophorectomy, perito-
neal washing, omentectomy, pelvic lymphadenectomy and para-
aortic lymphadenenctomy. Staging was based on the FIGO
classification. The resected lymph node counts were not con-
sidered for the completion of the lymphadenectomy. A pN1 case
was determined as having one or more lymph node metastasis in
pelvic or paraaortic lymph nodes.
Chemotherapy
Two hundred and forty-two (95.3%) patients received post-
operative chemotherapy after initial surgery. Second look opera-
tion or second reductive surgery was done by surgeon’s preference.
Combination therapy of cyclophosphamide and doxorubicin and
cisplatin (CAP) was as follows: one cycle consisted of a drip
infusion of 50–75mgm
 2 cisplatin for 3h accompanied by an i.v.
injection of 50mgm
 2 doxorubicin and 500mgm
 2 cyclopho-
sphamide and six cycles were given every 4 weeks. Paclitaxel and
platinum regimen consisted of an infusion of 175–180mgm
 2 of
paclitaxel and 50–75mgm
 2 of cisplatin or carboplatin
(AUC¼5–6). Other regimens included the combination che-
motherapy irinotecan hydrochloride and cisplatin (40 cases) and
irinotecan hydrochloride and mitomycin C (20 cases) and
irinotecan hydrochloride and etoposide (3 cases). One cycle of
irinotecan hydrochloride and platinum regimen consisted of a drip
infusion of 50–60mgm
 2 of cisplatin on day 1 and 50–60mgm
 2
of CPT-11 on day 1, 8, 15 and 1 week off and it was repeated every
4 weeks.
Response was evaluated with CT or MR images for patients with
measurable disease. A complete response (CR) was defined as the
complete disappearance of all detectable disease for at least 4
weeks. A partial response (PR) was defined as a 450% decrease in
tumour size for at least 4 weeks. Stable disease (SD) was defined as
the absence of any significant change in measurable lesions for at
least 4 weeks. Progressive disease (PD) was defined as the
appearance of a new lesion or a 425% increase in tumour size.
Serum levels of tumour markers including CA125 were not used
for response evaluation of chemotherapy in the present study.
The time to progression was defined as the interval from the
date of primary surgery until the date of recurrence or tumour
progression (PD). Survival duration was determined as the time
from the date of primary surgery until death or the date of last
follow-up contact.
Statistical methods
Kaplan–Meier method was used for calculation of patient survival
distribution. The significance of the survival distribution in each
group was tested by a generalized Wilcoxon test and the log-rank
test. The w
2-test and Student’s t-test for unpaired data were used
for statistical analysis. A P-value of o0.05 was considered
statistically significant. The Stat View software ver.5.0 (SAS
Institution Inc., Cary, NC, USA) was used to analyse the data.
RESULTS
Patients and tumours
The characteristics of the study population are summarized in
Table 1. Mean age was 52.4 years (range 23–73 years). Tumours
were 13% (33/254) stage Ia, 36% (92/254) stage Ic, 13% (33/254)
stage II, 31% (80/254) stage III, and 6% (16/254) stage IV,
respectively. There is no case with stage Ib tumours. Among 92
cases of stage Ic, there were 45 cases (49%) of Ic (capsule
Table 1 Characteristics of the patients
Characteristics No. of patients (%)
All cases 254
Age (years)
o55 147 (57.9)
455 107 (42.1)
FIGO Stage
Ia 33 (13.0)
Ic (ovarian surface) 3 (1.2)
Ic (capsule ruptured) 45 (17.7)
Ic (ascites/malignant washing) 44 (17.3)
II 33 (13.0)
IIIa,b 5 (2.0)
IIIc 75 (29.5)
IV 16 (6.3)
Residual tumour diameter
0cm 176 (69.3)
o1cm 18 (7.1)
41cm 60 (23.6)
Postoperative chemotherapy
CAP
a 76 (29.9)
Paclitaxel+platinum 103 (40.6)
Others 63 (24.8)
None 12 (4.7)
aCAP, cyclophosphamide+doxorubicin+cisplatin.
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sruptured), 3 cases (3%) of Ic (ovarian surface) and 44 cases (48%)
of Ic (ascites/malignant washing), respectively. In 75 stage IIIc
tumours, 15 cases (20%) were upstaged to stage IIIc because of
retroperitoneal lymph node metastasis and 20 patients (27%) had
both retroperitoneal lymph node metastasis and intra-peritoneal
disease. Residual tumour diameter after primary debulking
surgery was 0cm in 176 cases (69%), less than 1cm in 18 cases
(7%), and more than 1cm in 60 cases (24%), respectively.
Postoperative chemotherapy was offered for all patients, and 242
patients (95%) received anticancer drugs. Eight patients in stage Ia
and four patients with stage Ic (capsule ruptured) refused
postoperative chemotherapy.
Precise lymph node status according to pT distribution was
documented in Table 2. Lymph node metastasis was documented
in 3 of 36 patients (9%) in pT1a tumours, 7.1% in pT1c tumours,
13% in pT2, and 58% in pT3 tumours, respectively. Retro-
peritoneal lymph node metastasis in pT3 tumours was observed
significantly more frequent than in pT1, 2 tumours (58.0 vs 8.7%,
Po0.001, w
2-test).
Response of chemotherapy
Response judged with CT or MRI images was assessable in 73 cases
(29%) in 242 patients who received postoperative chemotherapy.
Only 5 of 30 cases (16%) responded to CAP regimen. Progressive
disease was documented in 23 patients (77%) and SD was observed
in 2 patients (7%). In 28 patients treated with paclitaxel and
platinum, response was observed in nine cases (32%) including
one case with CR. In the patients treated with other regimens,
response was observed in 3 of 10 patients (30%) treated with
irinotecan hydrochloride and cisplatin. There is no responder in
seven assessable patients who received combination with irino-
tecan hydrochloride and mitomycin C.
The median duration of progression-free survival for the
patients with measurable disease was 4 months (range, 1–20
months) in CAP regimen, 5 months (range, 1–21 months) in
paclitaxel and platinum, and 3 months (range, 2–20 months) in
irinotecan hydrochloride and cisplatin, respectively.
Clinical course
Average follow-up for all CCC patients in the present study is 47.4
months. Five-year progression-free survival and overall survival
was 84 and 88% in stage I, 57 and 70% in stage II, 25 and 33% in
stage III and 0 and 0% in stage IV, respectively (Figure 1).
Although there is no statistically significant difference in progres-
sion-free survival between patients with stage Ic (capsule ruptured)
and those with stage Ia (P¼0.11), progression-free survival of the
patients with stage Ic (ascites/malignant washing) and Ic (ovarian
surface) was significantly worse than that of stage Ic (capsule
ruptured) (P¼0.04)(Figure 2). Multiple regression survival
analysis for stage Ic patients with CCC revealed that positive
peritoneal cytology was the only independent prognostic factor
(P¼0.03; Relative risk, 3.40; 95% CI, 1.14–10.18). Cumulative
progression-free survival of pT1M0 patients with positive node
was significantly lower than those with negative node (Po0.01).
Five-year progression-free survival was 84% in pT1N0 patients and
56% in pT1N1 patients, respectively.
Progression-free survival curves of stage III, IV patients
according to the residual tumour diameter were shown in Figure 3.
Median progression-free survival duration was 39 months in the
Table 2 Rates of lymph node metastasis according to pT status
pT status pN1 pN0
Rate of Lymph Node
metastasis (%)
pT1a (n¼36) 3 33 9.1
pT1c (n¼99) 7 92 7.1
pT2 (n¼38) 5 33 13.1
pT3 (n¼81) 47 34 58.0
Total (n¼254) 62 192 24.4
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Figure 1 Progression-free survival and overall survival of patients depending on their FIGO stage. Five-year progression-free survival and overall survival
was 84 and 88% in stage I, 57 and 70% in stage II, 25 and 33% in stage III and 0 and 0% in stage IV, respectively. P-values in progression-free survival were as
follows: Stage I vs stage II, Po0.01; stage II vs stage III, Po0.01; stage III vs stage IV, P¼0.35. P-values in overall survival were as follows: Stage I vs stage II,
Po0.01; stage II vs stage III, Po0.01; stage III vs stage IV, P¼0.17.
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Figure 2 Progression-free survival of patients with FIGO stage I patients.
There is no significant difference between patients with stage Ic (capsule
ruptured) and those with stage Ia (P¼0.11). Survival of the patients with
stage Ic (ascites/malignant washing) and Ic (ovarian surface) was significantly
worse than that of stage Ic (capsule ruptured) (P¼0.04).
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spatients with no residual tumour, 7 months in those with the
tumor diameter less than 1cm, and 5 months in those with residual
tumour diameter more than 1cm, respectively. There is no
significant prognostic difference between the patients with the
tumour diameter less than 1cm and those with the tumour
diameter more than 1cm (P¼0.40). The patients with no residual
tumour had significantly better progression-free survival than
those with the tumour less than 1cm (P¼0.04) or those with
tumour diameter more than 1cm (Po0.01), respectively.
Multiple regression analysis in stage III and IV patients revealed
that chemotherapeutic regimen was not an independent prognostic
factor (P¼0.24) and only residual tumour diameter was an
independent prognostic factor in stage III and IV patients
(P¼0.02) (Table 3).
DISCUSSION
The present study and previous studies support that CCC of the
ovary tended to present at earlier stages. Proportion of stage I/II
tumours ranged from 59 to 71% (Yoonessi et al, 1984; Crozier et al,
1989; Jenison et al, 1989; Kennedy et al, 1989; O’Brien et al, 1993;
Behbakht et al, 1998; Sugiyama et al, 2000). One of the reasons for
the early detection was explained by the slow growing tumour
behaviour (Itamochi et al, 2002a) and frequent presentation of the
tumours as relatively large pelvic masses (Kennedy et al, 1989;
Behbakht et al, 1998). In the present study, the status of peritoneal
cytology was identified as an independent prognostic factor in
FIGO stage Ic patients. Although tumour progression was observed
in 5 (11%) of 45 stage Ic (capsule ruptured) tumours and one (3%)
of 33 stage Ia tumours, there is no significant survival difference
between two groups. Recent report analysing prognosis of early-
staged ovarian cancer including only 25 CCC cases (26.6%) in 94
carcinomas showed no statistical significant difference between
stages Ic preoperative vs intraoperative rupture (Leitao et al, 2004).
Another report including higher ratio of CCC patients identified
that stage Ic (capsule ruptured) patients showed significantly
poorer survival than stage Ia patients (Mizuno et al, 2003). The
present study implied the importance to remove the tumour mass
without intraoperative rupture, especially in CCC patients.
Even in stage I ovarian cancer including all histological
subtypes, the incidence of positive lymph nodes was not low,
ranging from 5.1 to 20% (Sakuragi et al, 2000; Cass et al, 2001;
Morice et al, 2003). It was reported that serous tumour had a
higher incidence of lymph node involvement than non-serous
tumors (Takeshima et al, 2005). Although the true incidence of
lymph node metastasis in CCC tumour had not been clear, the
present study revealed the frequency of metastasis in a large
number of the CCC patients. Lymph node metastasis was observed
in 3 of 36 patients (9.1%) in pT1a tumours, 7.1% in pT1c tumours,
10.8% in pT2 tumours, respectively. Fifteen (8.7%) of 173 patients
who had pT1 or pT2 tumors were upstaged as stage IIIc tumours
based on lymph node status. In general, prognostic significance of
retroperitoneal lymph node metastasis in early-staged ovarian
cancer patients was controversial. Survival rates with node-positive
disease were significantly lower in clinical stage I and II disease
(Kanazawa et al, 1999; Sakuragi et al, 2000; Negishi et al, 2004). In
contrast, another report showed that the prognoses for clinical
stage I/II patients with or without lymph node metastasis were
similar (Onda et al, 1998). In pT1 CCC patients of the present
study, lymph node status was identified as a strong prognostic
factor and it is essential to accurately evaluate the lymph node
status through complete surgical staging procedures. The study,
called Adjuvant ChemoTherapy in Ovarian Neolasm (ACTION),
revealed that no benefit of adjuvant chemotherapy was observed in
early-stage ovarian cancer with optimal surgical procedures
(Trimbos et al, 2003). In the present study, 12 patients with stage
Ia or stage Ic (capsule ruptured) refused to receive chemotherapy,
but there was no evidence of recurrence in median follow-up
period of 44 months (range: 6–63 months), which might support
the results of ACTION study.
Previous Japanese report have shown that the chemotherapeutic
effect was assessable in only 27 patients (26.7%) in 101 CCC cases,
in contrast it was assessable in 47% of serous adenocarcinoma
(Sugiyama et al, 2000). In our series of CCC patients, patients with
residual tumour diameter more than 1cm were documented in
only 60 (18%) of 254 cases, and the chemotherapeutic effect was
assessable in only in 73 cases (29%) in 242 patients who received
adjuvant chemotherapy. As the residual tumour after debulking
surgery often lacked measurable tumour diameter to evaluate the
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Figure 3 Progression-free survival of stage III, IV patients according to
the residual tumour (RT) diameter. There is no significant prognostic
difference between the patients with the tumour diameter less than 1cm
and those with the tumour diameter more than 1cm (P¼0.40). The
patients with no residual tumour had significantly better progression-free
survival than those with the tumour less than 1cm (P¼0.04) or those with
tumour diameter more than 1cm (Po0.01), respectively. Median
progression-free survival duration was 39 months in the patients with no
residual tumour, 7 months in those with the tumour diameter less than
1cm, and 5 months in those with residual tumour diameter more than
1cm, respectively.
Table 3 Multiple regression survival analysis for stage III, IV patients with
CCC
Variables Hazard ratio 95% confidence interval P
Age (years) 0.96
o54 1
455 0.99 0.60; 1.61
PS 0.67
01
1,2 1.06 0.79; 1.43
FIGO stage 0.22
III 1
IV 1.47 0.80; 2.70
Residual tumour 0.02
None 1
o1cm 2.23 0.89; 5.54
41cm 3.17 1.68; 6.00
Chemotherapy 0.24
CAP
a 1
Paclitaxel+platinum 0.56 0.48; 1.88
Others 0.95 0.32; 1.22
aCAP, cyclophosphamide+doxorubicin+cisplatin.
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seffects of adjuvant chemotherapy in CCC patients, it has been quite
difficult to select superior regimen.
There have been only a few reports to document the response of
anticancer agents for CCC patients, but each of them included
relatively small number of cases. The present study confirmed that
CAP regimen showed a low response rate and quite a high
incidence of PD in CCC patients as described previously
(Sugiyama et al, 2000). The combination chemotherapy consisting
of paclitaxel and platinum has been established as standard
therapy for ovarian cancer. One report of paclitaxel and platinum
regimen for CCC patients revealed that the response was observed
in two of nine cases (22%) (Enomoto et al, 2003), and the other
report of paclitaxel plus platinum chemotherapy showed the
response was observed in 9 of 15 cases (56%) (Ho et al, 2004).
These two studies including the present study suggested that
paclitaxel plus platinum regimen had higher response rate
compared to platinum-based chemotherapy. One report showed
survival benefit of conventional chemotherapy with paclitaxel and
platinum after complete surgery in CCC patients (Ho et al, 2003).
However, the results from our series of CCC patients showed that
there was no survival benefit with chemotherapy with paclitaxel
and platinum compared with CAP regimen in both early and
advanced cases. Irinotecan hydrochloride was preliminary intro-
duced for CCC patients in clinical settings (Shimizu et al, 1998;
Adachi et al, 1999; Kita et al, 2000), but there is no large clinical
trial for the treatment of CCC patients of the ovary. Further studies
are needed to establish the candidate regimen for CCC of the
ovary.
Recent studies have suggested that CCC tumour showed a
distinctive molecular behaviour from other histological subtypes.
In vitro study suggested that paclitaxel and irinotecan hydro-
chloride were the candidates for anti-neoplastic agents for CCC
(Itamochi et al, 2002b), but the present study has failed to prove
the survival benefit of these two drugs in CCC patients. Another
strategy for CCC tumours might be the additive use of molecular
targeting agents. It was reported that hepatocyte nuclear factor-1
beta (HNF-1 b) was a CCC-specific marker and had anti-apoptotic
effects in CCC cell lines (Tsuchiya et al, 2003). Another candidate
marker could be ABCF2, which belongs to the ATP-binding
cassette gene superfamily and is highly expressed in CCC and non-
responders for chemotherapy (Tsuda et al, 2005). Suppression of
CCC-specific molecular markers such as HNF-1 b or ABF2 may be
another strategy for the treatment of CCC of the ovary. The present
study clarified the significant prognostic importance of positive
peritoneal cytology in early-stage CCC disease, and no macro-
scopic residual tumour in advanced CCC tumours, respectively.
However, there was a little impact of chemotherapeutic effects on
both early and advanced diseases. Although further studies are
needed to identify effective agents in both anti-neoplastic agents
and molecular targeting agents, our study provides the funda-
mental characteristics of CCC of the ovary.
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